Dated: December 18, 2013.

Robert S. Balaban,
Scientific Director, DIR, NHLBI, NIH.

Lynn Suulsko,
NHLBI Project Clearance Liaison, National Institutes of Health.

[FR Doc. 2013–31430 Filed 12–31–13; 8:45 am]

BILLING CODE 4140–01–P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Substance Abuse and Mental Health Services Administration

Current List of Laboratories and Instrumented Initial Testing Facilities Which Meet Minimum Standards To Engage in Urine Drug Testing for Federal Agencies

AGENCY: Substance Abuse and Mental Health Services Administration, HHS.

ACTION: Notice.

SUMMARY: The Department of Health and Human Services (HHS) notifies federal agencies of the Laboratories and Instrumented Initial Testing Facilities (IITF) currently certified to meet the standards of the Mandatory Guidelines for Federal Workplace Drug Testing Programs (Mandatory Guidelines). The Mandatory Guidelines were first published in the Federal Register on April 11, 1988 (53 FR 11970), and subsequently revised in the Federal Register on June 9, 1994 (59 FR 29908); September 30, 1997 (62 FR 51118); April 13, 2004 (69 FR 19644); November 25, 2008 (73 FR 71858); December 10, 2008 (73 FR 75122); and on April 30, 2010 (75 FR 22809).

A notice listing all currently certified laboratories and IITF is published in the Federal Register during the first week of each month. If any laboratory or IITF certification is suspended or revoked, the laboratory or IITF will be omitted from subsequent lists until such time as it is restored to full certification under the Mandatory Guidelines.

Any laboratory or IITF that has withdrawn from the HHS National Laboratory Certification Program (NLCP) during the past month, it will be listed at the end and will be omitted from the monthly listing thereafter.

This notice is also available on the Internet at http://www.workplace.samhsa.gov.

FOR FURTHER INFORMATION CONTACT: Giselle Hersh, Division of Workplace Programs, SAMHSA/CSAP, Room 7–1051, One Choke Cherry Road, Rockville, Maryland 20857; 240–276–2600 (voice), 240–276–2610 (fax).

SUPPLEMENTARY INFORMATION: The Mandatory Guidelines were initially developed in accordance with Executive Order 12564 and section 503 of Public Law 100–71. The “Mandatory Guidelines for Federal Workplace Drug Testing Programs,” as amended in the revisions listed above, requires strict standards that laboratories and Instrumented Initial Testing Facilities (IITF) must meet in order to conduct drug and specimen validity tests on urine specimens for federal agencies.

To become certified, an applicant Laboratory or IITF must undergo three rounds of performance testing plus an on-site inspection. To maintain that certification, a Laboratory or IITF must participate in a quarterly performance testing program plus undergo periodic, on-site inspections.

Laboratories and IITF in the applicant stage of certification are not to be considered as meeting the minimum requirements described in the HHS Mandatory Guidelines. A Laboratory or IITF must have its letter of certification from HHS/SAMHSA (formerly: HHS/NIDA) which attests that it has met minimum standards.

In accordance with the Mandatory Guidelines dated November 25, 2008 (73 FR 71858), the following Laboratories and Instrumented Initial Testing Facilities (IITF) meet the minimum standards to conduct drug and specimen validity tests on urine specimens:

Instrumented Initial Testing Facilities (IITF)

None.

Laboratories

ACL Laboratories, 8901 W. Lincoln Ave., West Allis, WI 53227, 414–328–7840/800–827–7016 (Formerly: Bayshore Clinical Laboratory).


Alere Toxicology Services, 1111 Newton St., Greta, LA 70053, 504–361–8989/800–433–3823 (Formerly: Kroll Laboratory Specialists, Inc., Laboratory Specialists, Inc.).

Baptist Medical Center-Toxicology Laboratory, 11401 I–30, Little Rock, AR 72209–7056, 501–202–2783 (Formerly: Forensic Toxicology Laboratory Baptist Medical Center).

Clinical Reference Lab, 8433 Quivira Road, Lenexa, KS 66215–2802, 800–445–6917.

Doctors Laboratory, Inc., 2906 Julia Drive, Valdosta, GA 31602, 229–671–2281.

DrugScan, Inc., 200 Precision Road, Suite 200, Horsham, PA 19044, 800–235–4890.


Fortes Laboratories, Inc., 25749 SW Canyon Creek Road, Suite 600, Wilsonville, OR 97070, 503–486–1023.


Laboratory Corporation of America Holdings, 7207 N. Gessner Road, Houston, TX 77040, 713–856–8288/800–800–2387.

Laboratory Corporation of America Holdings, 69 First Ave., Kiritat, NJ 08869, 908–526–2400/800–437–4986 (Formerly: Roche Biomedical Laboratories, Inc.).


Laboratory Corporation of America Holdings, 1120 Main Street, Southaven, MS 38671, 866–827–8042/800–233–6339, (Formerly: LabCorp Occupational Testing Services, Inc.; MedExpress/National Laboratory Center).

LabOne, Inc. d/b/a Quest Diagnostics, 10101 Remer Blvd., Lenexa, KS 66219, 913–888–3927/800–873–8845 (Formerly: Quest Diagnostics Incorporated; LabOne, Inc.; Center for Laboratory Services, a Division of LabOne, Inc.).


MetroLab-Legacy Laboratory Services, 1225 NE 2nd Ave., Portland, OR 97232, 503–413–5295/800–950–5295.

Minneapolis Veterans Affairs Medical Center, Forensic Toxicology Laboratory, 1 Veterans Drive, Minneapolis, MN 55417, 612–725–2088.
Canadian laboratories will continue under DOT authority. The responsibility for conducting quarterly performance testing plus periodic on-site inspections of those LAPSA-accredited laboratories was transferred to the U.S. HHS, with the HHS’ NLCP contractor continuing to have an active role in the performance testing and laboratory inspection processes. Other Canadian laboratories wishing to be considered for the NLCP may apply directly to the NLCP contractor just as U.S. laboratories do.

Upon finding a Canadian laboratory to be qualified, HHS will recommend that DOT certify the laboratory (Federal Register, July 16, 1996) as meeting the minimum standards of the Mandatory Laboratories, certified through that (DOT) regulations. As of that date, the forensic urine drug testing as required program were accredited to conduct Laboratories certified through that PACIFIC TOXICOLOGY LABORATORIES, 9348 DeSoto Ave., Chatsworth, CA 91311, 800–326–6942 (Formerly: Centinela Hospital & Clinics, 301 Business Loop 7 West, Suite 208, Columbia, MO 65203, 573–882–1273.

US Army Forensic Toxicology Drug Testing Laboratory, 2490 Wilson St., Fort George G. Meade, MD 20755–5235, 301–677–7085.

*The Standards Council of Canada (SCC) voted to end its Laboratory Accreditation Program for Substance Abuse (LAPSA) effective May 12, 1998.

Summary: We, the U.S. Fish and Wildlife Service (Service), intend to prepare an environmental assessment (EA) to address the potential impacts of the issuance of a programmatic eagle take permit (permit) pursuant to the Bald and Golden Eagle Protection Act (BGEPA). The permit would authorize the taking of bald eagles associated with the construction and operation of the proposed Great Bay Wind Energy Project (Project) and implementation of an associated eagle conservation plan (ECP). The issuance of an eagle take permit is a Federal action subject to analysis under the National Environmental Policy Act of 1969 (NEPA). We provide this notice to announce the initiation of a public scoping period during which we invite other agencies and the public to submit written comments that provide suggestions and information on the scope of issues and alternatives to be addressed in the EA. We also announce that we will hold a public meeting where oral and written comments will also be accepted.

DATES: Written comments must be received on or before February 3, 2014. We will hold one public scoping meeting: see Public Meeting under SUPPLEMENTARY INFORMATION for the date, time, and location.

ADDRESSES: Comments concerning the issuance of the programmatic eagle take permit and the preparation of the associated EA should be identified as such, and may be submitted by one of the following methods:

- In-Person Drop-off, Viewing, or Pickup: Written comments will be accepted at the public meeting on Wednesday, January 15, 2014, or can be dropped off during regular business hours at the address above.

FOR FURTHER INFORMATION CONTACT: Ms. Sarah Nystrom, Regional Bald and Golden Eagle Coordinator, U.S. Fish and Wildlife Service, 300 Westgate Center Drive, Hadley, MA 01035; 413–253–8592 (telephone); Sarah_Nystrom@fws.gov (electronic mail). If you use a telecommunications device for the deaf, please call the Federal Information Relay Service at 1–800–877–8339.

SUPPLEMENTARY INFORMATION:

Introduction

We publish this notice under NEPA, as amended (42 U.S.C. 4321 et seq.), and its implementing regulations (40 CFR 1506.6), as well as in compliance with BGEPA (16 U.S.C. 668–688d).

Great Bay Wind I, LLC (Applicant), a subsidiary of Lavaca Wind, LLC which is an affiliate of Pioneer Green Energy, LLC, has applied for a programmatic bald eagle Programmatic Take Permit and Implementation of the Associated Eagle Conservation Plan for the Great Bay Wind Energy Project, Somerset County, Maryland.

AGENCY: Fish and Wildlife Service, Interior.

ACTION: Notice of intent, notice of scoping meeting, and request for comments.

SUMMARY: We, the U.S. Fish and Wildlife Service (Service), intend to prepare an environmental assessment (EA) to address the potential impacts of the issuance of a programmatic eagle take permit (permit) pursuant to the Bald and Golden Eagle Protection Act (BGEPA). The permit would authorize the taking of bald eagles associated with the construction and operation of the proposed Great Bay Wind Energy Project (Project) and implementation of an associated eagle conservation plan (ECP). The issuance of an eagle take permit is a Federal action subject to analysis under the National Environmental Policy Act of 1969 (NEPA). We provide this notice to announce the initiation of a public scoping period during which we invite other agencies and the public to submit written comments that provide suggestions and information on the scope of issues and alternatives to be addressed in the EA. We also announce that we will hold a public meeting where oral and written comments will also be accepted.

DATES: Written comments must be received on or before February 3, 2014. We will hold one public scoping meeting: see Public Meeting under SUPPLEMENTARY INFORMATION for the date, time, and location.

ADDRESSES: Comments concerning the issuance of the programmatic eagle take permit and the preparation of the associated EA should be identified as such, and may be submitted by one of the following methods:

- In-Person Drop-off, Viewing, or Pickup: Written comments will be accepted at the public meeting on Wednesday, January 15, 2014, or can be dropped off during regular business hours at the address above.

FOR FURTHER INFORMATION CONTACT: Ms. Sarah Nystrom, Regional Bald and Golden Eagle Coordinator, U.S. Fish and Wildlife Service, 300 Westgate Center Drive, Hadley, MA 01035; 413–253–8592 (telephone); Sarah_Nystrom@fws.gov (electronic mail). If you use a telecommunications device for the deaf, please call the Federal Information Relay Service at 1–800–877–8339.

SUPPLEMENTARY INFORMATION:

Introduction

We publish this notice under NEPA, as amended (42 U.S.C. 4321 et seq.), and its implementing regulations (40 CFR 1506.6), as well as in compliance with BGEPA (16 U.S.C. 668–688d).

Great Bay Wind I, LLC (Applicant), a subsidiary of Lavaca Wind, LLC which is an affiliate of Pioneer Green Energy, LLC, has applied for a programmatic eagle take permit for the taking of bald eagles (Haliaeetus leucocephalus) associated with the Project. We intend to gather the information necessary to prepare a draft EA to evaluate the impacts of, and alternatives to, the proposed issuance of a permit under BGEPA to the Applicant for the